Evergreened drugs or evergreened profits?

Area of Science:

• Pharmaceutical Economics
• Drug Patent Law
• Health Policy

Background:

• Branded drugs significantly increase prescription drug spending.
• Pharmaceutical companies employ patent extension strategies, known as "evergreening," to maintain high drug prices.

Approach:

• Reviewed literature on patent extension techniques in medical and marketing fields.
• Analyzed pricing of branded versus generic drugs using GoodRx.com and wholesaler data.
• Utilized FDA Orange Book for patent and formulation information.

Key Points:

• "Evergreening" tactics include formulation changes, dosing adjustments, and fixed-dose combinations (FDCs).
• The clinical benefit of FDCs in enhancing patient adherence is uncertain.
• Branded FDCs are typically more expensive than their individual components, with metformin combinations being a notable exception.

Conclusions:

• Patent extension tactics inflate drug costs with minimal patient benefit.
• Many FDCs offer no cost-justified clinical improvement over generic alternatives.
• Evergreening strategies generate profit without genuine innovation, burdening healthcare systems and patients.